F-18 Tetrafluoroborate PET/CT to find recurrent or residual differentiated thyroid cancer
F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer
This test will see if F-18 Tetrafluoroborate PET/CT finds recurrent or residual differentiated thyroid cancer better than standard F-18 FDG PET/CT in adults who had surgery and radioactive iodine and now have rising thyroglobulin or anti-thyroglobulin.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ankara University Academic / other |
| Locations | 2 sites (Ankara, Ankara and 1 other locations) |
| Trial ID | NCT07436455 on ClinicalTrials.gov |
What this trial studies
This interventional imaging study enrolls adults with differentiated thyroid cancer who have had surgery and radioactive iodine but now show rising serum thyroglobulin or anti-thyroglobulin and negative or equivocal I-131 whole-body scans. Participants undergo F-18 Tetrafluoroborate (TFB) PET/CT imaging and results are compared with standard F-18 FDG PET/CT and conventional imaging (neck ultrasound, thorax CT) for lesion detection. F-18 TFB is taken up via the sodium-iodide symporter (NIS) in thyroid cells, a mechanism similar to I-131 but with PET imaging sensitivity. The study aims to determine whether F-18 TFB improves detection of thyroid cancer lesions that other imaging misses.
Who should consider this trial
Good fit: Ideal candidates are adults (≥18) who had surgery and radioactive iodine for differentiated thyroid cancer, now have elevated serum Tg and/or ATg, negative or equivocal I-131 whole-body scans, a Karnofsky performance status ≥50, and can give informed consent.
Not a fit: Patients under 18, pregnant or breastfeeding individuals, or those without elevated Tg/ATg or with clear findings on standard imaging are unlikely to benefit from this imaging comparison.
Why it matters
Potential benefit: If successful, the technique could detect recurrent or residual disease more accurately and earlier, helping doctors choose the right follow-up or treatment.
How similar studies have performed: Previous small studies have shown F-18 TFB is superior to I-131 whole-body scans and have reported promising lesion detection versus FDG PET/CT, but larger direct comparative data remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Having undergone surgery for differentiated thyroid cancer and received radioactive iodine therapy * Being evaluated for lesion detection due to elevated serum Tg and/or ATg levels during post-treatment follow-up * Negative or equivocal I-131 whole-body scan findings * Karnofsky Performance Status ≥ 50 (or equivalent Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] performance status) * Giving written informed consent Exclusion Criteria: * Age under 18 years * Pregnancy or breastfeeding * Failure to provide written informed consent
Where this trial is running
Ankara, Ankara and 1 other locations
- Ankara University Medical School Nuclear Medicine Department — Ankara, Ankara, Turkey (Türkiye) (Recruiting)
- Hacettepe University Medical School Nuclear Medicine Department — Ankara, Ankara, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: Mine Araz, Assoc.Prof. — Ankara University Medical School Nuclear Medicine Department
- Study coordinator: Mine Araz, Assoc.Prof.Dr.
- Email: minesoylu@yahoo.com
- Phone: +905326667313
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.